MN SF1077

Establishes licensing standards for opioid addiction treatment programs, requiring medication orders from credentialed physicians, minimum eight random drug tests per year per client, and medical director oversight of all medication dispensing.

Implements take-home medication restrictions for methadone, limiting to single weekly doses during first 90 days, progressing to maximum two-week supply after one year and one-month supply after two years of continuous treatment.

Requires all chemical dependency treatment programs licensed by the commissioner to provide educational information to clients about opioid addiction treatment options, including medication-assisted treatments.

Mandates prescription monitoring program (PMP) reviews by medical directors at admission, quarterly thereafter, and monthly if multiple prescribers or prescriptions detected; authorizes Department of Human Services to routinely access PMP data for clients in opioid treatment programs.

Adds 25I-NBOMe, UR-144, XLR-11, AKB-48, 5-Fluoro-AKB-48, PB-22, and 5-Fluoro PB-22 to Schedule I controlled substances list, effective August 1, 2013.